IncobotulinumtoxinA to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 6-year Interim Results
Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea. Background: Sialorrhea is frequently a…Longitudinal Remote Monitoring with Wearable Technology in Parkinson Disease: Initiation of A Dyskinesia Insight Network Observational Study
Objective: Evaluate the utility of wearable digital health technology for identifying and characterizing levodopa-induced dyskinesia in real-world settings. Background: Patients with Parkinson disease (PwP) frequently…Continuous Subcutaneous Apomorphine Infusion (CSAI) Reduces OFF Periods and Extends Periods of GOOD ON Time: Heatmap Analysis of the TOLEDO Study
Objective: Use heatmap analysis to quantify and examine diurnal patterns of OFF and GOOD ON time periods throughout the day, and changes in the number…Quality of Life Improvements in Parkinson’s Disease for Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study
Objective: To assess whether exercise alone, or exercise combined with photobiomodulation (PBM) can improve the health-related quality of life (QoL) for people with Parkinson’s disease…Independent and Synergistic Effects of Subthalamic Temporal Interference Stimulation on Motor Symptoms in Parkinson’s Disease
Objective: To evaluate the independent effects of subthalamic transcranial temporal interference stimulation (tTIS) on motor symptoms in Parkinson’s Disease (PD) and to assess its…Effects of Dynamic Neuro-Cognitive Imagery on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial
Objective: To compare the effects of an experimental intervention (EI) based on DNI with a control intervention (CI) of equal volume and intensity, excluding MP…Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease
Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…Characterizing the Neural Signature of Parkinsonian Freezing of Gait During an Immersive Virtual Reality Paradigm
Objective: To characterize the neural signature of Freezing of gait (FOG) in Parkinson’s disease (PD) across multiple types of triggers. Background: FOG is among the…Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…Sustained Motor Symptom Efficacy With Long-Term Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Treatment – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the long-term effect on motor symptoms of advanced Parkinson’s disease (PD) following up to two years of treatment with LECIG by analysis…
- « Previous Page
- 1
- …
- 162
- 163
- 164
- 165
- 166
- …
- 181
- Next Page »